Cite

HARVARD Citation

    Rohaan, M. et al. (2022). MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial. Immuno-oncology technology. p. . [Online]. 
  
Back to record